Company news
Neogenomics, Inc. (NASDAQ:NEO) news
Every Neogenomics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
August 26, 2026
NeoGenomics Reports Second Quarter 2026 Results
July 28, 2026
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
July 20, 2026
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
July 9, 2026
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
July 7, 2026
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
June 25, 2026
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
June 17, 2026
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
June 15, 2026
Neo4j Acquires GraphAware to Launch Intelligence Analysis Alternative to Palantir Gotham
June 3, 2026
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
May 26, 2026
NeoGenomics Reports First Quarter 2026 Results
April 28, 2026
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
April 23, 2026
/C O R R E C T I O N -- Neo Performance Materials, Inc./
April 10, 2026
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
April 7, 2026
Neo Performance Materials Reports Fourth Quarter 2025 Results
March 19, 2026
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
March 16, 2026
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
February 25, 2026
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
February 17, 2026
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
February 12, 2026
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
January 27, 2026
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
January 12, 2026
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. "Jack" Kenny to its Board of Directors
December 30, 2025
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
December 30, 2025
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
December 15, 2025
NeoGenomics to Present New ctDNA Research at SABCS 2025
December 10, 2025
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
December 8, 2025
NeoGenomics to Participate in Upcoming Investor Conferences
November 6, 2025
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
October 30, 2025
NeoGenomics Reports Third Quarter 2025 Results
October 28, 2025
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
October 14, 2025
NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025
October 7, 2025
Natera Provides Update on Patent Litigation with NeoGenomics
August 29, 2025
Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera
August 29, 2025
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
July 30, 2025
NeoGenomics Reports Second Quarter 2025 Results
July 29, 2025
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
July 1, 2025
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
June 30, 2025
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
June 24, 2025
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
May 28, 2025
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
May 22, 2025
NeoGenomics to Participate in Upcoming June Investor Conferences
May 20, 2025
NeoGenomics Pays Off 1.25% Convertible Senior Notes
May 1, 2025
NeoGenomics Reports First Quarter 2025 Results
April 29, 2025
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
April 29, 2025
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
April 22, 2025
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
April 8, 2025
NeoGenomics Completes Acquisition of Pathline
April 7, 2025
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
April 1, 2025
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
March 18, 2025